HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms.

Abstract
Intravenous (IV) anti-D and IV immunoglobulin (IVIG) slow the Fcgamma receptor (FcgammaR)-mediated destruction of antibody-coated platelets in patients with immune thrombocytopenic purpura (ITP). This pilot study explored the mechanism of these immunoglobulin preparations by measuring interleukin-10 (IL-10), monocyte chemoattractant protein-1 (MCP-1), IL-6 and tumour necrosis factor alpha (TNFalpha), before and after infusion and by assessing the effect of FcgammaRIIa and FcgammaRIIIa polymorphisms on both cytokine and haematologic responses to anti-D. Following IVIG, only IL-10 was increased at 2 h and MCP-1 on day 7 (P < 0.05). In contrast, 2 h after anti-D infusion, plasma levels of all four cytokines were increased (P < 0.01); five of six patients with the highest MCP-1, IL-6 and TNFalpha levels had chills. Higher IL-10 levels correlated with platelet increases at 24 h and haemoglobin decreases at day 7 (P < 0.025). Patients with the FcgammaRIIa-131HH genotype had significantly higher MCP-1, IL-6 and TNFalpha levels. Patients with the FcgammaRIIIa-158VF genotype had higher platelet increments at day 7 (P < 0.05). Soluble CD16 (sCD16) was increased 2 h after IV anti-D; day 7 levels correlated with day 7 haemoglobin decreases (P < 0.01). In conclusion, the relationship of FcgammaRIIa and FcgammaRIIIa polymorphisms with both cytokine levels and platelet increments implicated these receptors in responses to anti-D and supported different mechanisms of FcgammaR interaction to those seen with IVIG.
AuthorsNichola Cooper, Nancy M Heddle, Masja Haas, Marion E Reid, Martin L Lesser, Howard B Fleit, B M R Woloski, James B Bussel
JournalBritish journal of haematology (Br J Haematol) Vol. 124 Issue 4 Pg. 511-8 (Feb 2004) ISSN: 0007-1048 [Print] England
PMID14984503 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD
  • Cytokines
  • Fc gamma receptor IIA
  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Isoantibodies
  • RHO(D) antibody
  • Receptors, IgG
  • Rh-Hr Blood-Group System
  • Rho(D) Immune Globulin
  • Prednisone
Topics
  • Adolescent
  • Adult
  • Antigens, CD (genetics)
  • Blood Platelets (immunology)
  • Cytokines (biosynthesis)
  • Female
  • Glucocorticoids (therapeutic use)
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Isoantibodies (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Phenotype
  • Pilot Projects
  • Platelet Count
  • Polymorphism, Genetic
  • Prednisone (therapeutic use)
  • Purpura, Thrombocytopenic, Idiopathic (blood, immunology, therapy)
  • Receptors, IgG (genetics)
  • Rh-Hr Blood-Group System (blood)
  • Rho(D) Immune Globulin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: